Menu
Back to Journals » Clinical Ophthalmology » Volume 3
The role of difluprednate ophthalmic emulsion in clinical practice
Authors Jamal, Callanan D
Published 29 June 2009 Volume 2009:3 Pages 381—390
DOI https://doi.org/10.2147/OPTH.S4460
Review by Single anonymous peer review
Peer reviewer comments 2
Karim N Jamal1,2, David G Callanan1
1Texas Retina Associates, Arlington, Texas, USA; 2Current affiliation: Retinal Consultants of Arizona, Phoenix, Arizona, USA
Abstract: The mainstay in the treatment of ocular inflammation, either post-surgical or endogenous, is the use of steroids. While these agents effectively address inflammation, they are not without their risks, including ocular hypertension and acceleration of cataract formation. The most notorious culprits are the strong steroids, such as prednisolone acetate and betamethasone. This review aims to cover the biochemistry and drug development of difluprednate, a novel synthetic strong steroid emulsion. In vivo pharmacokinetics as well as ocular distribution and metabolism are discussed, followed by a comprehensive summary of phase I, II, and III clinical trials evaluating safety and efficacy in patients suffering from postoperative inflammation or anterior uveitis. The objective is to provide an increased familiarity with this newly approved medication as a welcome addition to the ophthalmologist’s armamentarium.
Keywords: difluprednate, steroid, emulsion, ophthalmic surgery
© 2009 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.